Business Description
Astellas Pharma Inc
ISIN : JP3942400007
Description
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 3.43 | |||||
| Interest Coverage | 3.88 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.8 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.8 | |||||
| 3-Year EBITDA Growth Rate | -3 | |||||
| 3-Year EPS without NRI Growth Rate | -55.4 | |||||
| 3-Year FCF Growth Rate | -26 | |||||
| 3-Year Book Growth Rate | 6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 154.64 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.94 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.55 | |||||
| 9-Day RSI | 34.78 | |||||
| 14-Day RSI | 35.68 | |||||
| 6-1 Month Momentum % | 5.68 | |||||
| 12-1 Month Momentum % | -8.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | |||||
| Quick Ratio | 0.86 | |||||
| Cash Ratio | 0.3 | |||||
| Days Inventory | 268.02 | |||||
| Days Sales Outstanding | 106.95 | |||||
| Days Payable | 181.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.75 | |||||
| Dividend Payout Ratio | 2.45 | |||||
| 3-Year Dividend Growth Rate | 18.6 | |||||
| Forward Dividend Yield % | 4.81 | |||||
| 5-Year Yield-on-Cost % | 8.95 | |||||
| 3-Year Average Share Buyback Ratio | 1.1 | |||||
| Shareholder Yield % | -11.49 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.78 | |||||
| Operating Margin % | 3.63 | |||||
| Net Margin % | 3.09 | |||||
| FCF Margin % | 6.92 | |||||
| ROE % | 3.49 | |||||
| ROA % | 1.57 | |||||
| ROIC % | 1.84 | |||||
| ROC (Joel Greenblatt) % | 22.42 | |||||
| ROCE % | 3.21 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 49.93 | |||||
| Forward PE Ratio | 20.4 | |||||
| PE Ratio without NRI | 50.88 | |||||
| Shiller PE Ratio | 18.39 | |||||
| Price-to-Owner-Earnings | 36.31 | |||||
| PS Ratio | 1.54 | |||||
| PB Ratio | 1.78 | |||||
| Price-to-Free-Cash-Flow | 22.72 | |||||
| Price-to-Operating-Cash-Flow | 13.89 | |||||
| EV-to-EBIT | 44.67 | |||||
| EV-to-Forward-EBIT | 11.4 | |||||
| EV-to-EBITDA | 12.28 | |||||
| EV-to-Forward-EBITDA | 9.11 | |||||
| EV-to-Revenue | 1.87 | |||||
| EV-to-Forward-Revenue | 2.31 | |||||
| EV-to-FCF | 27.58 | |||||
| Price-to-Projected-FCF | 0.9 | |||||
| Price-to-Median-PS-Value | 0.61 | |||||
| Earnings Yield (Greenblatt) % | 2.24 | |||||
| FCF Yield % | 4.42 | |||||
| Forward Rate of Return (Yacktman) % | 0.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Astellas Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 10,932.511 | ||
| EPS (TTM) (€) | 0.186 | ||
| Beta | 0.16 | ||
| Volatility % | 24.05 | ||
| 14-Day RSI | 35.68 | ||
| 14-Day ATR (€) | 0.127839 | ||
| 20-Day SMA (€) | 9.61495 | ||
| 12-1 Month Momentum % | -8.86 | ||
| 52-Week Range (€) | 8.68 - 11.405 | ||
| Shares Outstanding (Mil) | 1,789.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Astellas Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Astellas Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Astellas Pharma Inc Frequently Asked Questions
What is Astellas Pharma Inc(STU:YPH)'s stock price today?
The current price of STU:YPH is €9.38. The 52 week high of STU:YPH is €11.41 and 52 week low is €8.68.
When is next earnings date of Astellas Pharma Inc(STU:YPH)?
The next earnings date of Astellas Pharma Inc(STU:YPH) is .
Does Astellas Pharma Inc(STU:YPH) pay dividends? If so, how much?
The Dividend Yield %  of Astellas Pharma Inc(STU:YPH) is 4.75% (As of Today), Highest Dividend Payout Ratio of Astellas Pharma Inc(STU:YPH) was 12.12. The lowest was 0.33. And the median was 0.47. The  Forward Dividend Yield % of Astellas Pharma Inc(STU:YPH) is 4.81%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers